{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:14:58Z","timestamp":1783617298243,"version":"3.55.0"},"reference-count":84,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interv Cardiol"],"abstract":"<jats:p>Protection against ischaemia\u2013reperfusion injury after revascularisation in acute myocardial infarction remains an enigma. Many targets have been identified, but after the failure of the recent Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention (CONDI2\/ERIC-PPCI) trial to show translation to clinical benefit, there is still no pharmacological or mechanical strategy that has translated to clinical practice. This article addresses the results of the CONDI2\/ERIC-PPCI trial in the context of previous studies of ischaemic conditioning, and then considers the prospects for other potential targets of cardioprotection. Finally, the authors examine the pitfalls and challenges in trial design for future investigation of cardioprotective strategies. In particular, this article highlights the need for careful endpoint and patient selection, as well as the need to pay attention to the biology of cardioprotection during the study.<\/jats:p>","DOI":"10.15420\/icr.2020.01","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T06:38:09Z","timestamp":1598855889000},"source":"Crossref","is-referenced-by-count":3,"title":["Cardioprotection for Acute MI in Light of the CONDI2\/ERIC-PPCI Trial: New Targets Needed"],"prefix":"10.15420","volume":"15","author":[{"given":"Joel P","family":"Giblett","sequence":"first","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heerajnarain","family":"Bulluck","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res 2013;113:451\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.112.300627; PMID: 23908332.","DOI":"10.1161\/circresaha.112.300627"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013;381:166\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(12)60916-7; PMID: 23095318.","DOI":"10.1016\/s0140-6736(12)60916-7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res 2016;119:676\u201395. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308736; PMID: 27539973.","DOI":"10.1161\/circresaha.116.308736"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Heusch G. Critical issues for the translation of cardioprotection. Circ Res 2017;120:1477\u201386. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310820; PMID: 28450365.","DOI":"10.1161\/circresaha.117.310820"},{"key":"ref4","unstructured":"Hausenloy DJ, Kharbanda RK, M\u00f8ller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2\/ERIC-PPCI): a single-blind randomised controlled trial. Lancet 2019;394:1415\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32039-2; PMID:31500849."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013;369:901\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1208200; PMID: 24004117.","DOI":"10.1056\/nejmoa1208200"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121\u201335. https:\/\/doi.org\/10.1056\/NEJMra071667; PMID: 17855673.","DOI":"10.1056\/nejmra071667"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. Eur Heart J 2017;38:774\u201384. https:\/\/doi:org\/10.1093\/eurheartj\/ehw224; PMID: 27354052.","DOI":"10.1093\/eurheartj\/ehw224"},{"key":"ref8","unstructured":"Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 2017;38:935\u201341. https:\/\/doi.org\/10.1093\/eurheartj\/ehw145; PMID: 27118196."},{"key":"ref9","unstructured":"Hausenloy DJ, Barrabes JA, B\u00f8tker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol 2016;111:70. https:\/\/doi.org\/10.1007\/s00395-016-0588-8; PMID: 27766474."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Heusch G. 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res Cardiol 2018;113:15. https:\/\/doi.org\/10.1007\/s00395-018-0673-2; PMID: 29516255.","DOI":"10.1007\/s00395-018-0673-2"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124\u201336. https:\/\/doi.org\/10.1161\/01.CIR.74.5.1124; PMID: 3769170.","DOI":"10.1161\/01.cir.74.5.1124"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic \u201cpreconditioning\u201d protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893\u20139. https:\/\/doi.org\/10.1161\/01.CIR.87.3.893; PMID: 7680290.","DOI":"10.1161\/01.cir.87.3.893"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 2009;119:820\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.809723; PMID: 19188504.","DOI":"10.1161\/circulationaha.108.809723"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113\u201351. https:\/\/doi.org\/10.1152\/physrev.00009.2003; PMID: 14506302.","DOI":"10.1152\/physrev.00009.2003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Johnsen J, Pryds K, Salman R, et al. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol 2016;111:10. https:\/\/doi.org\/10.1007\/s00395-016-0529-6; PMID: 26768477.","DOI":"10.1007\/s00395-016-0529-6"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264\u201372. https:\/\/doi.org\/10.1161\/01.CIR.88.3.1264; PMID: 8353888.","DOI":"10.1161\/01.cir.88.3.1264"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993;72:1293\u20139. https:\/\/doi.org\/10.1161\/01.RES.72.6.1293; PMID: 8495557.","DOI":"10.1161\/01.res.72.6.1293"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Lambiase PD, Edwards RJ, Cusack MR, et al. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 2003;41:1174\u201382. https:\/\/doi.org\/10.1016\/S0735-1097(03)00055-X; PMID: 12679219.","DOI":"10.1016\/s0735-1097(03)00055-x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Stein AB, Tang XL, Guo Y, et al. Delayed adaptation of the heart to stress: late preconditioning. Stroke 2004;35(11 Suppl 1):2676\u20139. https:\/\/doi.org\/10.1161\/01.STR.0000143220.21382.fd; PMID: 15459441.","DOI":"10.1161\/01.str.0000143220.21382.fd"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Hear Circ Physiol 2003;285:H579\u201388. https:\/\/doi.org\/10.1152\/ajpheart.01064.2002; PMID: 12860564.","DOI":"10.1152\/ajpheart.01064.2002"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Schmidt MR, Smerup M, Konstantinov IE, et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007;292:H1883\u201390. https:\/\/doi.org\/10.1152\/ajpheart.00617.2006; PMID: 17172279.","DOI":"10.1152\/ajpheart.00617.2006"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881\u20133. https:\/\/doi.org\/10.1161\/01.CIR.0000043806.51912.9B; PMID: 12460865.","DOI":"10.1161\/01.cir.0000043806.51912.9b"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(09)62001-8; PMID: 20189026.","DOI":"10.1016\/s0140-6736(09)62001-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Lonborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010;3:34\u201341. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.109.905521; PMID: 20118154.","DOI":"10.1161\/circinterventions.109.905521"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sorensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 2010;96:1710\u20135. https:\/\/doi.org\/10.1136\/hrt.2010.199430; PMID: 20956486.","DOI":"10.1136\/hrt.2010.199430"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Freixa X, Bellera N, Ortiz-Perez JT, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Hear J 2012;33:103\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehr297; PMID: 21846677.","DOI":"10.1093\/eurheartj\/ehr297"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zhao CM, Yang XJ, Yang JH, et al. Effect of ischaemic postconditioning on recovery of left ventricular contractile function after acute myocardial infarction. J Int Med Res 2012;40:1082\u20138. https:\/\/doi.org\/10.1177\/147323001204000327; PMID: 22906281.","DOI":"10.1177\/147323001204000327"},{"key":"ref28","unstructured":"Thuny F, Lairez O, Roubille F, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012;59:2175\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.026; PMID: 22676937."},{"key":"ref29","unstructured":"Hahn JY, Song YB, Kim EK, et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of Postconditioning on Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction (POST) randomized trial. Circulation 2013;128:1889\u201396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001690; PMID: 24068776."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"White SK, Frohlich GM, Sado DM, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2015;8(1 Pt B):178\u201388. https:\/\/doi.org\/10.1016\/j.jcin.2014.05.015; PMID: 25240548.","DOI":"10.1016\/j.jcin.2014.05.015"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Sloth AD, Schmidt MR, Munk K, et al. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2014;35:168\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/eht369; PMID: 24031025.","DOI":"10.1093\/eurheartj\/eht369"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Gaspar A, Louren\u00e7o AP, Pereira M\u00c1, et al. Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI). Basic Res Cardiol 2018;113:14. https:\/\/doi.org\/10.1007\/s00395-018-0672-3; PMID: 29516192.","DOI":"10.1007\/s00395-018-0672-3"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Stiermaier T, Jensen J-O, Rommel K-P, et al. Combined intrahospital remote ischemic perconditioning and postconditioning improves clinical outcome in ST-elevation myocardial infarction. Circ Res 2019;124:1482\u201391. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.314500; PMID: 30929570.","DOI":"10.1161\/circresaha.118.314500"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 2015;373:1408\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1413534; PMID: 26436207.","DOI":"10.1056\/nejmoa1413534"},{"key":"ref35","unstructured":"Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 2015;373:1397\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1413579; PMID: 26436208."},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand 2012;56:30\u20138. https:\/\/doi.org\/10.1111\/j.1399-6576.2011.02585.x; PMID: 22103808.","DOI":"10.1111\/j.1399-6576.2011.02585.x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Heusch G, Gersh BJ. ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! Eur Heart J 2016;37:200\u2013202. https:\/\/doi.org\/10.1093\/eurheartj\/ehv606; PMID: 26508160.","DOI":"10.1093\/eurheartj\/ehv606"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Garratt KN, Whittaker P, Przyklenk K. Remote ischemic conditioning and the long road to clinical translation: lessons learned from ERICCA and RIPHeart. Circ Res 2016;118:1052\u20134. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.308102; PMID: 27034272.","DOI":"10.1161\/circresaha.115.308102"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Kharbanda RK, Nielsen TT, Redington AN. Translation of remote ischaemic preconditioning into clinical practice. Lancet 2009;374:1557\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(09)61421-5; PMID: 19880021.","DOI":"10.1016\/s0140-6736(09)61421-5"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ovize M, Thibault H, Przyklenk K. Myocardial conditioning: opportunities for clinical translation. Circ Res 2013;113:439\u201350. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300764; PMID: 23908331.","DOI":"10.1161\/circresaha.113.300764"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Giblett JP, West NEJ, Hoole SP. Cardioprotection for percutaneous coronary intervention \u2013 reperfusion quality as well as quantity. Int J Cardiol 2014;177:786\u201393. https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.041; PMID: 25453404.","DOI":"10.1016\/j.ijcard.2014.10.041"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Heusch G, Gersh BJ. Is cardioprotection salvageable? Circulation 2020;141:415\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044176; PMID: 32078426.","DOI":"10.1161\/circulationaha.119.044176"},{"key":"ref43","unstructured":"Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711\u201320. https:\/\/doi.org\/10.1016\/S0735-1097(99)00418-0; PMID: 10577561."},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.061; PMID: 15936605.","DOI":"10.1016\/j.jacc.2005.02.061"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Garcia-Dorado D, Garc\u00eda-del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol 2014;177:935\u201341. https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.203; PMID: 25449504.","DOI":"10.1016\/j.ijcard.2014.09.203"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Hear J 2011;32:867\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehq492; PMID: 21196444.","DOI":"10.1093\/eurheartj\/ehq492"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Bulluck H, Sirker A, Loke YK, et al. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int J Cardiol 2016;202:228\u201337. https:\/\/doi.org\/10.1016\/j.ijcard.2015.09.005; PMID: 26402450.","DOI":"10.1016\/j.ijcard.2015.09.005"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia\/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19:9\u201311. https:\/\/doi.org\/10.1007\/s10557-005-6892-4; PMID: 15883751.","DOI":"10.1007\/s10557-005-6892-4"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Hausenloy DJ, Yellon DM. Taking lizard saliva to heart. Eur Heart J 2012;33:1426\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehr382; PMID: 21992997.","DOI":"10.1093\/eurheartj\/ehr382"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Giblett JP, Axell RG, White PA, et al. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol 2016;15:99. https:\/\/doi.org\/10.1186\/s12933-016-0416-3; PMID: 27431258.","DOI":"10.1186\/s12933-016-0416-3"},{"key":"ref51","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827; PMID: 27295427."},{"key":"ref52","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141; PMID: 27633186."},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Read PA, Hoole SP, White PA, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011;4:266\u201372. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.110.960476; PMID: 21586690.","DOI":"10.1161\/circinterventions.110.960476"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"McCormick LM, Hoole SP, White PA, et al. Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv 2015;8:292\u2013301. https:\/\/doi.org\/10.1016\/j.jcin.2014.09.014; PMID: 25700752.","DOI":"10.1016\/j.jcin.2014.09.014"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Hear J 2012;33:1491\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehr309; PMID: 21920963.","DOI":"10.1093\/eurheartj\/ehr309"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5:288\u201395. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.112.968388; PMID: 22496084.","DOI":"10.1161\/circinterventions.112.968388"},{"key":"ref57","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225; PMID: 26630143."},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Giblett JP, Clarke S, Zhao T, et al. The role of glucagon-like peptide 1 loading on periprocedural myocardial infarction during elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial. Am Heart J 2019;215:41\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2019.05.013; PMID: 31277053.","DOI":"10.1016\/j.ahj.2019.05.013"},{"key":"ref59","unstructured":"Ibanez B, Macaya C, S\u00e1nchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 2013;128:1495\u20131503. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003653; PMID: 24002794."},{"key":"ref60","unstructured":"Roolvink V, Ib\u00e1\u00f1ez B, Ottervanger JP, et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:2705\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.522; PMID: 27050189."},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Heusch G, Skyschally A, Gres P, et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008;29:2265\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehn337; PMID: 18621770.","DOI":"10.1093\/eurheartj\/ehn337"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Steg PG, Lopez-de-S\u00e0 E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care 2013;2:270\u20139. https:\/\/doi.org\/10.1177\/2048872613489305; PMID: 24222839.","DOI":"10.1177\/2048872613489305"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93\u20138. https:\/\/doi.org\/10.1042\/bj3070093; PMID: 7717999.","DOI":"10.1042\/bj3070093"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473\u201381. https:\/\/doi.org\/10.1056\/NEJMoa071142; PMID: 18669426.","DOI":"10.1056\/nejmoa071142"},{"key":"ref65","unstructured":"Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55:1200\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.052; PMID: 20298926."},{"key":"ref66","unstructured":"Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med 2015;373:1021\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1505489; PMID: 26321103."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"B\u00f8tker HE, Cabrera\u2010Fuentes HA, Ruiz\u2010Meana M, et al. Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST\u2010segment elevation myocardial infarction. J Cell Mol Med 2020;24:2717. https:\/\/doi.org\/10.1111\/jcmm.14953; PMID: 31967733.","DOI":"10.1111\/jcmm.14953"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Yang XM, Liu Y, Cui L, et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 2013;18:251\u201362. https:\/\/doi.org\/10.1177\/1074248412467692; PMID: 23233653.","DOI":"10.1177\/1074248412467692"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Yang XM, Cui L, Alhammouri A, et al. Triple therapy greatly increases myocardial salvage during ischemia\/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther 2013;27:403\u201312. https:\/\/doi.org\/10.1007\/s10557-013-6474-9; PMID: 23832692.","DOI":"10.1007\/s10557-013-6474-9"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Yang XM, Liu Y, Cudi L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 2013;27:109\u201315. https:\/\/doi.org\/10.1007\/s10557-012-6436-7; PMID: 23318690.","DOI":"10.1007\/s10557-012-6436-7"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Vilahur G, Guti\u00e9rrez M, Casani L, et al. Protective effects of ticagrelor on myocardial injury after infarction. Circulation 2016;134:1708\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024014; PMID: 27789556.","DOI":"10.1161\/circulationaha.116.024014"},{"key":"ref72","unstructured":"Bulluck H, Chan MHH, Bryant JA, et al. Platelet inhibition to target reperfusion injury trial: Rationale and study design. Clin Cardiol 2019;42:5\u201312. https:\/\/doi.org\/10.1002\/clc.23110; PMID: 30421441."},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Stone GW, Martin JL, de Boer M-J, et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366\u201375. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.108.840066; PMID: 20031745.","DOI":"10.1161\/circinterventions.108.840066"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"David SW, Khan ZA, Patel NC, et al. Evaluation of intracoronary hyperoxemic oxygen therapy in acute anterior myocardial infarction: The IC\u2010HOT study. Catheter Cardiovasc Interv 2019;93:882\u201390. https:\/\/doi.org\/10.1002\/ccd.27905; PMID: 30265429.","DOI":"10.1002\/ccd.27905"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Pryds K, Terkelsen CJ, Sloth AD, et al. Remote ischaemic conditioning and healthcare system delay in patients with ST-segment elevation myocardial infarction. Heart 2016;102:1023\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2015-308980; PMID: 26911520.","DOI":"10.1136\/heartjnl-2015-308980"},{"key":"ref76","unstructured":"Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia\/reperfusion injury. J Am Coll Cardiol 2019;73:89\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.086; PMID: 30621955."},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010;3:602\u201310. dhttps:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.110.959080; PMID: 21156928.","DOI":"10.1161\/circinterventions.110.959080"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Ternant D, Ivanes F, Prunier F, et al. Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling. Sci Rep 2017;7:10709. https:\/\/doi.org\/10.1038\/s41598-017-11352-4; PMID: 28878319.","DOI":"10.1038\/s41598-017-11352-4"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Bulluck H, Hammond-Haley M, Weinmann S, et al. Myocardial infarct size by cmr in clinical cardioprotection studies: insights from randomized controlled trials. JACC Cardiovasc Imaging 2017;10:230\u201340. https:\/\/doi.org\/10.1016\/j.jcmg.2017.01.008; PMID: 28279370.","DOI":"10.1016\/j.jcmg.2017.01.008"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Bulluck H, Dharmakumar R, Arai AE, et al. Cardiovascular magnetic resonance in acute ST-segment-elevation myocardial infarction: Recent advances, controversies, and future directions. Circulation 2018;137:1949\u201364. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030693; PMID: 29712696.","DOI":"10.1161\/circulationaha.117.030693"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Kim HW, Van Assche L, Jennings RB, et al. Relationship of T2-weighted MRI myocardial hyperintensity and the ischemic area-at-risk. Circ Res 2015;117:254\u201365. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.305771; PMID: 25972514.","DOI":"10.1161\/circresaha.117.305771"},{"key":"ref82","unstructured":"Ibanez B, Aletras AH, Arai AE, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J Am Coll Cardiol 2019;74:238\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.024; PMID: 31296297."},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol 2019;114:45. https:\/\/doi.org\/10.1007\/s00395-019-0756-8; PMID: 31617010.","DOI":"10.1007\/s00395-019-0756-8"}],"container-title":["Interventional Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.icrjournal.com\/articles\/cardioprotection-for-acute-mi-in-light","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:46:16Z","timestamp":1783615576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.icrjournal.com\/articleindex\/icr.2020.01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":84,"URL":"https:\/\/doi.org\/10.15420\/icr.2020.01","relation":{},"ISSN":["1756-1485","1756-1477"],"issn-type":[{"value":"1756-1485","type":"electronic"},{"value":"1756-1477","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"article-number":"e13"}}